Investors are now faced with a pivotal decision between the stable, low-cost Fidelity MSCI Health Care Index ETF and the high-risk, high-reward State Street XBI, as recent performance highlights the divergence in risk and return profiles.
For investors weighing healthcare exchange-traded funds, the choice often comes down to breadth versus precision. Fidelity’s MSCI Health Care Index ETF, or FHLC, offers wide exposure to the U.S. healthcare industry at a notably low cost, while State Street’s SPDR S&P Biotech ETF, known as XBI, is built for those who want a much narrower bet on biotechnology and are prepared for sharper swings in price. The comparison matters because both funds sit in the same broad sector, yet they pursue very different risks and return patterns.
According to Fidelity, FHLC tracks the MSCI USA IMI Health Care 25/50 Index and was launched on 21 October 2013. The fund holds a diversified mix of large-, mid- and small-cap healthcare companies, which helps explain its more stable profile. The Motley Fool’s figures show FHLC with an expense ratio of 0.08%, a trailing 12-month yield of 1.2%, and a beta of 0.58, suggesting lower volatility than the wider market. Its biggest positions include Eli Lilly, Johnson & Johnson and AbbVie, so performance is still influenced by a handful of major names even within a broad mandate.
XBI, by contrast, is designed for investors who want direct exposure to biotechnology rather than the wider healthcare universe. State Street says the ETF launched on 31 January 2006 and uses an equal-weighted approach, which means smaller holdings can matter as much as larger ones. That structure can amplify gains when emerging drug developers or diagnostics firms deliver, but it can also magnify losses when trials fail or regulatory setbacks hit. The Motley Fool’s data put XBI’s one-year return at 81.5%, far ahead of FHLC, but the same table shows a much steeper five-year maximum drawdown of 63.9%, underscoring how much more turbulent the fund has been.
The cost and income difference is also stark. State Street lists XBI’s expense ratio at 0.35%, several times higher than FHLC’s, while The Motley Fool’s analysis shows FHLC yielding 1.2% versus just 0.3% for XBI. That gap reflects the funds’ construction as much as their holdings: FHLC is built as a broad core holding for investors who want diversified healthcare exposure with less drama, while XBI is better suited to those making a tactical bet on biotech innovation. In practical terms, FHLC looks like the steadier choice for long-term investors, while XBI is the more aggressive play for those willing to accept greater volatility in pursuit of stronger upside.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
